Skip to main content
Elliot Stieglitz, MD, Pediatric Hematology & Oncology, San Francisco, CA, UCSF Benioff Children's Hospital Oakland

ElliotStieglitzMD

Pediatric Hematology & Oncology • San Francisco, CA

Assistant Professor

Request Appointment

Overview of Dr. Stieglitz

Dr. Elliot Stieglitz is a pediatric hematologist/oncologist in San Francisco, CA and is affiliated with multiple hospitals in the area, including UCSF Benioff Children's Hospital Oakland and Kaiser Permanente San Francisco Medical Center. He received his medical degree from Stony Brook University Health Sciences Center School of Medicine and has been in practice 9 years. He is one of 54 doctors at UCSF Benioff Children's Hospital Oakland and one of 28 doctors at Kaiser Permanente San Francisco Medical Center who specialize in Pediatric Hematology & Oncology. He also speaks multiple languages, including Spanish. He has more than 60 publications and over 500 citings.

Education & Training

  • University of California (San Francisco)
    University of California (San Francisco)Fellowship, Pediatric Hematology/Oncology, 2011 - 2014
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Pediatrics, 2008 - 2011
  • Stony Brook University Health Sciences Center School of Medicine
    Stony Brook University Health Sciences Center School of MedicineClass of 2008

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2011 - 2026
  • NY State Medical License
    NY State Medical License 2009 - 2012
  • American Board of Pediatrics Pediatrics
  • American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

  • K08 Clinical Investigator Award NHLBI @ NIH, 2017
  • Individual Investigator Award American Cancer Society, 2016
  • Rally Grant Rally Foundation for Childhood Cancer Research, 2016
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Downregulating Notch Counteracts KrasG12D-Induced ERK Activation and Oxidative Phosphorylation in Myeloproliferative Neoplasm  
    Erik A Ranheim, David Yang, Warren S Pear, Lan Zhou, Mignon Loh, Eric Padron, Elliot Stieglitz, Nature

Abstracts/Posters

  • In Vitro-Selected Nanobody-Based Cellular Therapy Targeting CD72 for Treatment of Refractory B-Cell Malignancies
    Elliot Stieglitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • DNA Methylation As a Biomarker of Outcome in JMML: An International Effort Towards Clinical Implementation
    Elliot Stieglitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Promising New Combination of Drugs Identified to Treat Juvenile Myelomonocytic Leukemia
    Promising New Combination of Drugs Identified to Treat Juvenile Myelomonocytic LeukemiaApril 7th, 2023
  • Baby Diagnosed with Rare Blood Cancer Saved by Miracle Treatment
    Baby Diagnosed with Rare Blood Cancer Saved by Miracle TreatmentSeptember 26th, 2019
  • Liver Cancer Drug for Adults Saves the Life of an Infant with Deadly Leukemia
    Liver Cancer Drug for Adults Saves the Life of an Infant with Deadly LeukemiaSeptember 12th, 2019
  • Join now to see all

Other Languages

  • Spanish

Hospital Affiliations

External Links

Dr. Elliot Stieglitz, Dr. Elliot Stieglitz, MD, Dr. E Stieglitz